Asmaloc Syrup is manufactured by Sharif Pharmaceuticals Ltd. Asmaloc Syrup contains 120 mg/5 ml Theophylline. It is Theophylline & related drugs class drug.
Asmaloc is a bronchodilator, structurally classified as a Methylxanthine. Asmaloc has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation and suppression of the response of the airways to stimuli. Asmaloc also increases the force of contraction of diaphragmatic muscles. The half-life of Asmaloc is influenced by a number of known variables. In adult nonsmokers with uncomplicated asthma the half-life ranges from 3 to 9 hours
This is used for the symptomatic treatment of reversible bronchoconstriction associated with bronchial asthma, chronic obstructive pulmonary emphysema, chronic bronchitis and related bronchospastic disorders.
|Weight:||120 mg/5 ml|
|Therapeutic Class:||Theophylline & related drugs|
|Manufacturer:||Sharif Pharmaceuticals Ltd|
|Last Updated:||November 22, 2020 at 6:15 pm|
Table Of contents
Asmaloc contains Theophylline 120 mg/5 ml. Asmaloc Dosage:
Dosages are adjusted to maintain serum theophylline concentrations that provide optimal relief of symptoms with minimal side effects. Most of the controlled release preparations may be administered every 12 hours in adults while administration every 8 hours may be necessary in some children with markedly rapid hepatic metabolism of theophylline. The recommended dosages for achieving serum theophylline concentrations within the accepted therapeutic range is as follow:
- 1-6 months: 10 mg/Kg/day
- 6 months-1 year: 15 mg/Kg/day
- 1-9 years: 24 mg/Kg/day
- 10-16 years: 18 mg/Kg/day
- Adults: 10-15 mg/Kg/day
The following side effects have been observed:
Gastrointestinal: Nausea, vomiting, epigastric pain and diarrhoea.
Central nervous system: Headache, irritability, restlessness, insomnia, muscles twitching.
Cardiovascular: Palpitation, tachycardia, hypotension. circulatory failure.
Respiratory: Tachypnoea.Renal: Potentiation of diuresis.
Others: Alopecia, hyperglycemia, rash etc.
Careful consideration is needed for various interacting drugs and physiologic conditions that can alter Asmaloc clearance. Dosage adjustment is required prior to initiation of Asmaloc therapy, prior to increases in Asmaloc dose, and during follow up. The dose of Asmaloc selected for initiation of therapy should be low and, if tolerated, increased slowly over a period of time.
Allopurinol, cimetidine, norfloxacin, ciprofloxacin, erythromycin, oral contraceptives and propranolol increase serum theophylline levels. Phenytoin, methotrexate and rifampicin lead to decreased serum theophylline levels
Pregnancy Lactation use
Pregnancy: It is not known whether Asmaloc can cause foetal harm when administered to pregnant woman.Xanthines should be given to a pregnant woman only if clearly needed.
Nursing mother: Asmaloc is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. Serious adverse effects in the infant are unlikely unless the mother has toxic serum Asmaloc concentrations.
Hypersensitivity to xanthine derivatives. It is also contraindicated in patients with active peptic ulcer disease and in individuals with underlying seizure disorders (unless receiving appropriate anti-convulsing medication).
Asmaloc should not be administered concurrently with other xanthine. Use with caution in patients with hypoxemia, hypertension, or those with history of peptic ulcer. Do not attempt to maintain any dose that is not tolerated.
Symptoms may include nausea, vomiting, gastrointestinal irritation, cramps, convulsions, tachycardia & hypotension. The stomach contents should be emptied & supportive measures employed to maintain circulation, respiration & fluid & electrolyte balance. Electrocardiographic monitoring should be carried out & in severe poisoning charcoal haemoperfusion should be used.
Interaction with other Medicine
Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children